|
Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)
RECRUITINGN/ASponsored by University of Michigan
Actively Recruiting
PhaseN/A
SponsorUniversity of Michigan
Started2022-08-05
Est. completion2028-03-31
Eligibility
Age2 Days – 17 Years
Healthy vol.Accepted
Locations50 sites
View on ClinicalTrials.gov →
NCT05376267
Summary
This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest. The study team hypothesizes that longer durations of cooling may improve either the proportion of children that attain a good neurobehavioral recovery or may result in better recovery among the proportion already categorized as having a good outcome.
Eligibility
Age: 2 Days – 17 YearsHealthy volunteers accepted
Inclusion criteria: * Age 2 days to \< 18 years with corrected gestational age of at least 38 weeks * Chest compressions for at least 2 minutes * Coma or encephalopathy after resuscitation from Out-of-Hospital Cardiac Arrest (OHCA) * Requires continuous mechanical ventilation through endotracheal tube or tracheostomy * Definitive temperature control device initiated * Randomization within 6 hours of Return of Spontaneous Circulation (ROSC) * Informed consent from Legally Authorized Representative (LAR) including intent to maintain life support for 120 hours Exclusion criteria: * Glasgow Coma Motor Score (GCMS) = 6 * LAR does not speak English or Spanish * Duration of Cardiopulmonary Resuscitation (CPR) \> 60 minutes * Severe hemodynamic instability with continuous infusion of epinephrine or norepinephrine of 2 micrograms per kilogram per minute (μg/kg/minute) or initiation of Extracorporeal membrane oxygenation (ECMO) * Pre-existing severe neurodevelopmental deficits with Pediatric Cerebral Performance Category (PCPC) =5 or progressive degenerative encephalopathy * Pre-existing terminal illness, unlikely to survive to one year * Cardiac arrest associated with brain, thoracic, or abdominal trauma * Active and refractory severe bleeding prior to randomization * Extensive burns or skin lesions incompatible with surface cooling * Planned early withdrawal of life support before 120 hours * Sickle cell anemia * Pre-existing cryoglobulinemia * Non-fatal drowning in ice covered water * Central nervous system tumor with ongoing chemotherapy * Previous enrollment in P-ICECAP trial * Prisoner * Chronic hypothermia * New post-cardiac arrest diabetes insipidus * Pregnancy
Conditions4
Cardiac Arrest, Out-Of-HospitalHeart DiseaseHypothermia, InducedHypoxia-Ischemia, Brain
Locations50 sites
University of Alabama at Birmingham / Children's of Alabama
Birmingham, Alabama, 35233
Phoenix Children's Hospital
Memorial Health - Miller Children's and Women's Hospital of Long Beach
Children's Hospital of Los Angeles
Find trials near these locations
Heart Disease trials in PhoenixHeart Disease trials in TucsonHeart Disease trials in Long BeachHeart Disease trials in Los AngelesHeart Disease trials in SacramentoHeart Disease trials in San FranciscoHeart Disease trials in MiamiHeart Disease trials in ChicagoHeart Disease trials in IndianapolisHeart Disease trials in BaltimoreHeart Disease trials in BostonHeart Disease trials in MinneapolisAll trials in ArizonaAll trials in CaliforniaAll trials in FloridaAll trials in IllinoisAll trials in IndianaAll trials in MarylandAll trials in MassachusettsAll trials in MinnesotaAll trials in MissouriAll trials in NebraskaAll trials in New YorkAll trials in North CarolinaAll trials in OhioAll trials in OregonAll trials in PennsylvaniaAll trials in TennesseeAll trials in TexasAll trials in Wisconsin
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorUniversity of Michigan
Started2022-08-05
Est. completion2028-03-31
Eligibility
Age2 Days – 17 Years
Healthy vol.Accepted
Locations50 sites
View on ClinicalTrials.gov →
NCT05376267